What Does GSK’s GF Score\u2122 Tell Us?<\/p>\n
The GF Score\u2122 is a composite metric that evaluates a company\u2019s overall quality by examining financial strength, profitability, growth, valuation, and momentum. GSK\u2019s GF Score\u2122 of 73\/100 indicates a generally healthy company with solid fundamentals but some areas for improvement.<\/p>\n
Metric Rating GF Score\u2122 73 Financial Strength 5\/10 Profitability 8\/10 Growth 6\/10 Valuation 6\/10 Momentum 2\/10<\/p>\n
GSK\u2019s strongest area is profitability, scoring 8 out of 10, supported by expanding operating margins (currently 20.7%) and a healthy net margin of 14.52%. Growth is moderate, with a 3-year revenue growth rate of 3.4% and earnings growth of 8.1% over three years. Financial strength is middling at 5\/10, reflecting a moderate debt-to-equity ratio of 1.03 and an Altman Z-Score in the grey zone at 2.11, indicating some financial stress but no immediate bankruptcy risk. Momentum is the weakest factor, scoring just 2\/10, suggesting limited recent price acceleration. For further details, visit the GSK stock page<\/a>.<\/p>\n What Are Gurus and Insiders Doing with GSK?<\/p>\n Institutional interest in GSK remains significant but mixed. According to GuruFocus\u2019 proprietary 13F data, 16 premium gurus currently hold GSK shares. In recent quarters, 6 gurus have added to their positions while 11 have trimmed holdings, indicating a cautious but engaged stance among top investors. This nuanced activity suggests that while some see value or growth potential, others may be taking profits or reallocating capital.<\/p>\n Regarding insider activity, there have been no reported insider purchases or sales in the past 3 or 12 months. The absence of insider transactions leaves institutional moves as the primary signal of confidence or concern.<\/p>\n What This Means for Investors<\/p>\n For income-focused investors, GSK presents a dividend stock with a reasonably attractive yield and a moderate payout ratio that supports sustainability despite recent negative dividend growth trends. The company\u2019s modest overvaluation by GF Value\u2122 tempers enthusiasm somewhat but does not negate the appeal of its cash returns. Mixed guru activity and a middling financial strength score suggest that investors should monitor developments closely, particularly regulatory progress on oncology drugs like Jemperli that could drive future growth. Overall, GSK remains a viable option for dividend investors seeking exposure to a large-cap pharmaceutical with a diversified portfolio. More insights can be found on the GSK stock page<\/a> or by exploring the GuruFocus Stock Screener<\/a>.<\/p>\n Frequently Asked Questions<\/p>\n What is GSK’s GF Score\u2122?<\/p>\n GSK\u2019s GF Score\u2122 of 73\/100 reflects a company with solid profitability and moderate growth, balanced by average financial strength and valuation metrics. It suggests a generally healthy business with some areas to watch.<\/p>\n Is GSK’s dividend safe?<\/p>\n With a dividend yield of 3.47%, a payout ratio of 57%, and a recent decline in dividend growth of -5.7% over three years, GSK\u2019s dividend appears moderately safe but investors should be mindful of the slowing growth trend.<\/p>\n What is GSK’s P\/E ratio compared to historical?<\/p>\n GSK\u2019s current trailing twelve months P\/E ratio is 16.26x, slightly above its 5-year median P\/E of 14.02x, indicating the stock trades at a modest premium relative to its historical valuation.<\/p>\n This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email\u00a0protected]<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"On August 24, 2026, GSK PLC (NYSE: GSK) announced that the FDA has accepted for priority review its…\n","protected":false},"author":2,"featured_media":111607,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[623,20785,34328,45751,18],"class_list":["post-112181","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-article","tag-gsk","tag-gurufocus","tag-gurufocus-news","tag-news"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117167311150099119","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/112181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=112181"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/112181\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/111607"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=112181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=112181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=112181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"2091843268043251712.png\"\/](\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/08\/2091843268043251712.png\")
<\/p>\n